ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

Stimulus Bill Gives NIH A $10 Billion Boost Over Two Years, Puts Pressure On Institutes to Make Rapid Funding Decisions

February 13, 2009

FDA Advisors Okay NCI Toxicology Proposals, Write New Clinical Guidelines, Approve AIN DA

October 19, 1979

Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show

November 28, 1986

Jako Bows Out with Blast At NCI, Calls For IOM Review Of Cancer Program

April 15, 1988

NCCN Updates Myeloma Clinical Practice Guidelines

September 26, 2003

NCI Advisors Approve Three New Grant Programs; RFA, PA Available.

July 5, 2002